Unity Biotechnology Receivables

Unity Biotechnology posts a receivables of $0 as of March 2025. That compares with $1.6M in the prior-year period — down 100.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Unity Biotechnology's receivables was $1.6M. The latest reading is $0 — a 100.0% year-over-year decrease (period ending March 2025). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Unity Biotechnology's financial statement story. At $0, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for UBX's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Unity Biotechnology's other metric pages and overview cover the third.

Judging Unity Biotechnology against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in receivables easier to interpret. Start with $0 here, then scan peer and history charts to see if the gap is persistent.